Breast cancer is the most common cause of cancer mortality in women worldwide (GLOBOCAN 2012, <http://globocan.iarc.fr/Pages/fact_sheets_population.aspx>). Triple negative-breast cancer (TNBC) is characterised by lack of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). This subtype accounts for 15--20% of all breast cancers ([@bib1]). It is a heterogeneous disease that partake distinct histopathological features and clinical behaviour. Epidemiological studies revealed that TNBC is associated with young age (\<40) and more frequently in African--American and black ethnicity ([@bib1]). TNBC tumours represent the most aggressive phenotype with relatively high recurrence rates ([@bib6]). Patients with TNBC do not respond to endocrine therapy or HER2 targeted therapy, and treatment are based on a combination of commonly used breast cancer therapies including surgery, radiation and chemotherapy regimens.

Clinical trials conducted on TNBC using cisplatin-based regimes as neoadjuvant therapy found that the response rate to single-agent cisplatin was only 21%. An improved response rate was seen using a combination of paclitaxel/fluorouracil, doxorubicin and cyclophosphamide but this was still only 45% ([@bib24]). TNBC and *BRCA* mutations associated tumour share common pathologies. Poly (ADP-ribose) polymerase (PARP) inhibitor is a class of anti-tumour agents which targets tumours with *BRCA* mutations but could only benefit a small group of patients ([@bib15]). Combining inhibitors of PARP and PI3K were shown to be effective in primary tumour xenografts where tumours had no *BRCA* mutations, and the clinical outcome of this trial is awaiting ([@bib11]). To date, the current treatment options for TNBC do not demonstrate promising clinical outcomes and often results in poor treatment response and overall survival rate. This is also partly due to the lack of biomarkers to envisage which groups of patients are likely to respond to specific chemotherapeutic and targeted therapies nor are there reliable biomarkers which have been identified to be used as a screening marker. Hence, there is a substantial need for discovering a predictive biomarker for diagnosis that could identify patients with this aggressive and fast growing tumour at an earlier stage to improve the prognosis. With limited targeted therapy currently available for TNBC, it is also important to have a marker for disease monitoring and evaluate the need to change therapy if the treatment response is poor.

MicroRNA (miRNA) has a critical regulatory role in gene expression and is involved in breast carcinogenesis ([@bib21]). Currently, there are over 1800 miRNAs identified in human (miRBase release 20) and these regulate \>50% of the genes. Several lines of evidence have shown that miRNAs are differentially expressed in cancerous tissues when compared with adjacent non-tumour counterparts ([@bib3]; [@bib29]). Expression profiles of miRNAs have been reported to form more defined cluster with similar tumour types than mRNA expression. Numerous studies suggested that miRNAs are highly stable and can be detected in the circulation ([@bib16]). It has also been reported that miRNA patterns are unique in the cancers of breast ([@bib18]), colon ([@bib17]), gastric ([@bib28]), ovary ([@bib22]) and prostate ([@bib2]). The recognition of miRNAs in the circulation marks the milestone in cancer diagnosis and therapeutic application. Detection of circulating miRNAs can serve as non-invasive and cost-effective markers to identify high-risk patients, which are beneficial in clinical setting in terms of diagnosis, prognosis and treatment response. Published data reported that the levels of miR-30a were lower in patients with breast cancer, and showed improved sensitivity and specificity compared with conventional circulating tumour markers (CEA and CA153) ([@bib33]). Furthermore, high level of miR-155 was associated with better clinical outcome in TNBC patients ([@bib8]).

Our group has established a robust platform to profile miRNA in various diseases ([@bib17]; [@bib13]; [@bib18]), and have identified a panel of breast cancer-associated miRNAs from plasma, which can potentially serve as screening tool for breast cancer patients ([@bib18]). In this study, we aim to uncover TNBC-associated miRNAs in the circulation based on our established platform. The profiles of miRNAs in TNBC were compared with those in non-TNBC, as well as healthy controls. Candidate miRNAs were selected based on the differential expression between these groups, validated in an independent cohort, and correlated with clinical outcomes.

Materials and Methods
=====================

Study design and patients samples
---------------------------------

In the marker discovery phase, miRNA expression from plasma of TNBC (*n*=5), non-TNBC (*n*=5) and healthy controls (*n*=5) were profiled. In the validation phase, candidate miRNAs were selected and validated in a small scale independent cohort of breast cancer patients (*n*=90). Those miRNAs were then verified in primary breast tissues and pre- and post-operative plasma samples. Potential miRNAs were then validated in a large cohort of patients (*n*=252). The workflow of the study design is shown in [Figure 1](#fig1){ref-type="fig"}. A total of 67 TNBC female patients and 95 non-TNBC female patients were recruited with informed consent through the Queen Mary Hospital, the Tung Wah Hospital and the Hong Kong Sanatorium and Hospital and through the Hong Kong Hereditary Breast Cancer Family Registry. We also recruited 90 healthy controls from the Queen Mary Hospital and the Tung Wah Hospital who were confirmed not to have breast cancer and have no personal history of other cancers. The study was approved by the Institutional Review Board of the University of Hong Kong and the Hong Kong Sanatorium and Hospital. Patients\' demographic and clinical outcomes were listed in [Table 1](#tbl1){ref-type="table"}.

Samples processing and miRNA extraction
---------------------------------------

Total RNA were extracted from tissues and paraffin blocks using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer\'s instructions. Blood samples were centrifuged at 1600 g for 10 min at 4 °C, and plasma was carefully transferred into new tubes followed by further centrifugation at 1600 g for 10 min at 4 °C. Total RNA containing small RNA using Trizol LS reagent and miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s suggestion protocol with the following modifications: 1 ml Trizol LS reagent was added to 500 *μ*l plasma samples. After phase separation, 1.5 volume of 100% ethanol was added to the aqueous phase and the mixture was loaded into the miRNeasy column (Qiagen) according to the manufacturer\'s instructions. The concentration of all miRNA samples were quantified by NanoDrop 1000 (Thermo Scientific, Wilmington, DE, USA).

MiRNA expression profiling
--------------------------

In the marker discovery phase, we profiled 5 age- and sex- matched individuals from plasma of patients with TNBC, non-TNBC and healthy controls using a miRCURY LNA Array V3.R (Exiqon, Vedbaek, Denmark), which contained 752 human miRNAs. This system is a real-time PCR-based array containing a panel of 384 well-established mature miRNA assays. The kit contains all reagents and primers, reverse transcription and qPCR. In brief, a poly-A tail is added to the mature miRNA template and then synthesised to cDNA by a poly-T primer with a 3′ degenerate anchor and 5′ universal tag. The cDNA is amplified by miRNA-specific and LNA-enhanced forward and reverse primers (Exiqon). SYBR Green PCR will be performed in LC480 Real-time PCR system (Roche, Basel, Switzerland).

MiRNA validation by real-time RT--PCR
-------------------------------------

MiRNAs were polyadenylated and reverse transcribed into cDNA by using miScript Reverse Transcription Kit (Qiagen) according to the manufacturer\'s instructions. Real-time qPCR was performed using LightCycler 480 SYBR Green I Master (Roche) in Roche LC480 system. The miRNA-specific forward primers sequences were designed based on the miRNA sequences obtained from the miRBase database (release 20; <http://mirbase.org/>). The miRNA-specific primer sequences for qPCR were listed in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. Each sample was run in duplicates for analysis. The expression levels of miRNAs were normalised to miR-484. Fold change of miRNA was calculated by the equation 2^−ΔΔCt^. ΔCt was calculated by subtracting the Ct values of miR-484 from the Ct values of the miRNA-of-interest. ΔΔCt was then calculated by subtracting ΔCt of the control from ΔCt of cancer.

Statistical analysis
--------------------

The significance of plasma miRNA levels was determined by Mann--Whitney test, Wilcoxon test, *χ*^2^-test or Kruskal--Wallis test where appropriate. The sensitivity and specificity were calculated according to the standard formulas. Multivariate logistic regression model was established and leave-one-out cross validation to find the best logistic model. Receiver-operator characteristics (ROC) curves were established for discriminating patients with or without breast cancer. The optimal sensitivity and specificity from ROC curves were determined by a commonly used method. All *P*-values are two-sided and *P*\<0.05 was considered statistically significant. All statistical calculations were performed by GraphPad PRISM 5 software (GraphPad Software, La Jolla, CA, USA).

Results
=======

Discovery of TNBC-associated miRNAs
-----------------------------------

We profiled miRNA expression in plasma from patients with TNBC (*n*=5), non-TNBC (*n*=5) and age-matched healthy controls (*n*=5) using miRCURY LNA Array. With a cutoff value of 2-fold difference, there were 10 differentially expressed miRNAs in TNBC. As shown in [Table 2](#tbl2){ref-type="table"}, there were three upregulated (miR-342-3p, miR-23b-3p and miR-92a-3p) and seven downregulated miRNAs (miR-21 miR-16, miR-143, miR-185, miR-199a-3p, miR-199a-5p and miR-221) in TNBC when compared with non-TNBC and healthy controls.

Selection of potential markers
------------------------------

Ten putative miRNAs derived from microarray were validated in plasma of 30 breast cancer patients and 30 healthy controls by real-time PCR. The expression of these miRNAs was shown in [Figure 2A](#fig2){ref-type="fig"}, and we selected a marker that could differentiate TNBC from non-TNBC. Results showed that the expression levels of miR-16, miR-21, miR-199a-5p, miR-92a-3p and miR-342-3p were significantly different between TNBC, non-TNBC and healthy controls and was consistent with the array data. Receiver-operator characteristics curve analysis of miR-16 (area under curve (AUC)=0.7289, 95% CI: 0.60--0.86, *P*=0.002), miR-21 (AUC=0.8333, 95% CI: 0.73--0.94, *P*\<0.0001) and miR-199a-5p (AUC=0.8463, 95% CI: 0.78--0.91, *P*\<0.0001), miR-92a-3p (AUC=0.7789, 95% CI: 0.66--0.90, *P*=0.0002), miR-342-3p (AUC=0.7283, 95% CI: 0.60--0.86, *P*=0.002) ([Figure 2B](#fig2){ref-type="fig"}). Therefore, these five miRNAs were chosen for further validation.

To examine whether these miRNAs were associated with tumour load, we compared the expression of these miRNAs in paired primary breast tissues, as well as pre- and post-operative plasma samples. The expression levels of miR-92a-3p and miR-324-3p were higher in primary breast cancer tumour tissues (*n*=11) when compared with the adjacent non-tumour counterparts ([Figure 3A](#fig3){ref-type="fig"}). On the other hand, miR-16, miR-21 and miR-199a-5p had a lower expression in tumour tissues, which was in line with the data in plasma. Moreover, we compared the expression levels of miR-16, miR-21, miR-199a-5p, miR-92a-3p and miR-342-3p between pre-operative (pre) and post-operative (post) plasma (*n*=10). Results showed that the expression levels of miR-16, miR-21 and miR-199a-5p were reversed in the post-operative plasma, however, reversal of expression levels were not seen in miR-92a-3p and miR-342-3p ([Figure 3B](#fig3){ref-type="fig"}). These data confirmed that miR-16, miR-21 and miR-199a-5p were associated with tumour load, which may potentially be used as a diagnostic marker for TNBC.

Further validation of markers
-----------------------------

Mir-16, miR-21 and miR-199a-5p were then further validated in a large cohort of patients containing 67 TNBC (stage 0 & I, *n*=27; stage II, *n*=25; stage III & IV, *n*=13), 95 non-TNBC (stage 0 & I, *n*=39; stage II, *n*=39; stage III & IV, *n*=17) and 90 healthy controls. Results showed that all three miRNAs showed a significant lower expression in TNBC than non-TNBC ([Figure 4](#fig4){ref-type="fig"}). Receiver-operator characteristics curve analyses revealed that miR-16 (AUC=0.7983, 95% CI: 0.71--0.88, *P*\<0.0001), miR-21 (AUC=0.8740, 95% CI: 0.81--0.94, *P*\<0.0001), miR-199a-5p (AUC=0.8838, 95% CI: 0.83--0.94, *P*\<0.0001) were differentiating TNBC from healthy controls and non-TNBC patients. Results showed that miR-199a-5p with the highest ROC value maybe a potential biomarker to discriminate TNBC from non-TNBC.

Correlation with clinical outcomes
----------------------------------

To correlate if the plasma level of miR-199a-5p is associated with tumour stage, patients were then stratified into TNM stages. Plasma miR-199a-5p expression in TNBC patients had significant difference when compared with healthy controls (stage 0 & I, *P*\<0.001; stage II, *P*\<0.001; stage III, *P*\<0.001; stage IV, *P*\<0.001) ([Figure 5](#fig5){ref-type="fig"}). In addition, there was a trend of decrease in the expression level of miR-199a-5p with tumour stage, in which patients with stage IV breast cancer had a significantly lower expression than those with stage 0 & I disease (*P*=0.028).

More importantly, the plasma levels of miR-199a-5p were categorised into tumour subtypes, that is, ER/PR+ (luminal), HER2+ and TNBC. Result showed that tumours bearing hormone receptors (luminal and HER2+) had a higher expression of miR-199a-5p than in TNBC, implicating hormone receptors may have a role in the regulation of miR-199-5p in breast cancer.

Discussion
==========

Triple-negative breast cancer represents an aggressive phenotype of breast cancer. It has been well-documented that TNBC is associated with advanced stage, family history and occurs in patients who are *BRCA1* mutation carriers ([@bib14]). Epidermal growth factor receptor (EGFR) was one of the first anti-cancer agents which was used to treat TNBC. However, \<20% of the patients responded to anti-EGFR agents in the clinical setting, suggesting other signal pathways were prevailing in these group of patients ([@bib4]). Others suggest that anti-angiogenesis-based drugs can result in a better response in TNBC in the neoadjuvant setting but whether survival would be affected is still very much unknown ([@bib23]; [@bib30]). Lack of available targeted therapy is one of the obstacles in treating TNBC, which could partially explain the poor prognosis in patients with TNBC compared with other breast cancer subtypes ([@bib7]). MiRNA profiling could help to understand the pathogenesis of TNBC, can be implicated in the clinical application as biomarkers for diagnosis and prognosis. In the present study, we used our established platform to examine the miRNAs that can discriminate TNBC from other breast cancer subtypes.

We have listed several differentially expressed miRNAs in TNBC and compared their expression in pre- and post-operative plasma ([Table 2](#tbl2){ref-type="table"} and [Figure 3B](#fig3){ref-type="fig"}). We have demonstrated that miR-16, miR-21 and miR-199a-5p had a significant lower expression in TNBC than in non-TNBC, in which only miR-199a-5p was associated with tumour stage ([Figure 5](#fig5){ref-type="fig"}). In our previous study, miR-16 and miR-21 were upregulated in primary tissues and blood samples in non-TNBC cases ([@bib18]). Interestingly, we found that these miRNAs were downregulated in the plasma, as well as in cancerous tissues of TNBC patients ([Figure 4](#fig4){ref-type="fig"}). Piles of evidence showed that miR-21 was one of the ER-responsive miRNAs in cancers ([@bib26]; [@bib27]), which could partly explain the low expression of miR-21 in TNBC. Recently, a panel of miRNAs (including miR-16) has been identified to be used as a predictive marker for overall survival in TNBC cases ([@bib5]). Furthermore, a four-miRNA signature (miR-16, miR-25, miR-222 and miR-324-3p) has been associated with increased risk of breast cancer ([@bib10]). However, the exact functions of miR-16 in breast cancer have not been clearly defined. The tumour suppressive role of miR-16 was linked to cyclin E regulation in breast cancer ([@bib20]). In the case of hepatitis B virus-related hepatocellular carcinoma, downregulation of miR-15 and miR-16 was observed in the viral RNA ([@bib31]). These studies revealed the tumour suppressor function of miR-16, which reverberated our data on the low expression of miR-16 in more aggressive subtype of breast cancer.

The action of miR-199a-5p in the development of cancers has not been studied until recently. Higher expression of miR-199a-5p was found in cancerous tissues than non-tumour counterparts and was associated with lymph-node metastasis in patients with gastric cancer ([@bib9]). Forced expression of miR-199a-5p has been shown to stimulate EMT process and metastasis in gastric cancer through serum response factor ([@bib34]). On the other hand, the anti-tumorigenic activity of miR-199a-5p was seen in multiple myeloma cells by targeting endothelial-cell migration and adhesion molecules (VCAM-1 and ICAM-1) ([@bib19]). Recently, a three-miRNA plasma panel with low expression of miR-199a-5p could discriminate patients with COPD and squamous cell carcinomas. This early-response miRNA has contributed to the 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced pulmonary carcinogenesis ([@bib12]). There has only been one study which demonstrated that miR-199a-5p is a regulator of autophagy and sensitised breast cancer cells to irradiation ([@bib32]). Consistent with our current findings, miR-199a-5p was downregulated in cancers of prostate, colon and bladder, in which it could suppress surface-exposed glucose-related protein (GRP78) and enhance chemosensitivity to chemotherapy in cancer cells ([@bib25]).

It is widely believed that circulating miRNAs are released from the tumour cells, and yet the level of specific miRNAs would be altered before and after removal of tumours. There is a possibility of hormonal influence, which regulates the miRNA biogenesis and the subsequent cellular responses in breast carcinogenesis. These hypotheses warrant further investigation and provide the basis for the understanding of the molecular mechanisms of specific miRNAs. Though the results were promising, our study was limited by small sample number of TNBC patients and those with stage IV disease. The evaluation of the association between metastasis and expression of miR-199a-5p would be useful and is awaited to be proven with a large sample size. Nevertheless, results of this study provide a non-invasive screening tool to identify patients with TNBC phenotype, which offers a more convenient and sensitive method when compared with immunohistochemistry.

To the best of our knowledge, this is the first study to unravel low expression of miR-199a-5p in TNBC subtype when compared with other breast cancer subtypes in the circulation. With the inclusion of non-TNBC subtypes in this study, we could have a clearer picture of the changes in expression levels in TNBC subtypes, which was not common in most of the studies. The expression of miR-199a-5p was associated with a disease stage, which could be potentially useful as a predictive marker for early diagnosis for TNBC in the clinical settings. This study provides the basis for drug development, which may serve as a target for treating TNBC patients.
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![**Workflow of the study design.**](bjc2015143f1){#fig1}

![**Small scale validation of miRNAs in TNBC, non-TNBC and healthy controls (*n*=90).** (**A**) Box plot of plasma levels of three upregulated (miR-342-3p, miR-23b-3p and miR-92a-3p) and seven downregulated miRNAs (miR-21 miR-16, miR-143, miR-185, miR-199a-3p, miR-199a-5p and miR-221) in TNBC patients. The expression of miRNAs was normalised to miR-484. The lines inside the boxes represent the medians. The boxes mark the interval between the 25th and 75th percentiles. The whiskers denote the interval between the 10th and 90th percentiles. Statistically significant differences were determined using Mann--Whitney tests. (**B**) Receiver-operator characteristics (ROC) curve analysis of miRNAs to discriminate TNBC patients from healthy controls. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.](bjc2015143f2){#fig2}

![**Selection and validation of potential miRNAs.** (**A**) Fold change of miRNAs in primary breast tumour/non-tumour adjacent tissues. (**B**) Comparison of miRNAs levels in plasma of TNBC patients (*n*=10) before (pre-operative) and 14 days after (post-operative) removal of the breast tumour. Expression levels of the miRNAs are normalised to miR-484. Statistically significant differences were determined using Wilcoxon tests. \**P*\<0.05, \*\**P*\<0.01.](bjc2015143f3){#fig3}

![**Large scale validation of three miRNAs in a cohort of 252 patients.** Box plot of plasma levels of miR-16 miR-21 and miR-199a-5p in TNBC patients. The expression of miRNAs was normalised to miR-484. The lines inside the boxes represent the medians. The boxes mark the interval between the 25th and 75th percentiles. The whiskers denote the interval between the 10th and 90th percentiles. Statistically significant differences were determined using Mann--Whitney tests. Receiver-operator characteristics (ROC) curve analysis of miRNAs to discriminate TNBC patients from healthy controls. \*\*\**P*\<0.001.](bjc2015143f4){#fig4}

![**Association of miR-199a-5p expression with tumour stage.** Plasma miR-199a-5p expression in TNBC patients were stratified by TMN stage and had statistical significance with healthy controls. \*\**P*\<0.01, \*\*\**P*\<0.001.](bjc2015143f5){#fig5}

###### Clinical characteristics of TNBC and non-TNBC breast cancer patients in validation set

                                         **TNBC (*****n*****=67)**   **Non-TNBC (*****n*****=95)**   ***P-*****value**
  ------------------------------------- --------------------------- ------------------------------- -------------------
  Age (years; mean (s.d.))                      55.7 (12.6)                   55.1 (11.8)                 0.4753
  **Histological type**                                                                                   0.1166
  DCIS                                               0                             3                          
  IDC                                               59                            85                          
  ILC                                                1                             3                          
  Mixed (ILC+IDC)                                    2                             1                          
  Others                                             5                             3                          
  **Histological tumour grade**                                                                           0.7058
  1                                                  1                            11                          
  2                                                 14                            41                          
  3                                                 41                            28                          
  NA                                                11                            12                          
  Bilateral cancer (at the same time)                1                             1                      1.0000
  **Operation**                                                                                           0.1695
  No                                                 2                             0                          
  Yes                                               65                            95                          
  **Lymph-node (N)**                                                                                      0.7833
  N0                                                43                            53                          
  N1                                                11                            27                          
  N2                                                 3                             8                          
  N3                                                 8                             7                          
  NX                                                 2                             0                          
  **Distant metastasis**                                                                            
  **Before surgery**                                                                                          
   No                                               65                            91                      1.0000
   Yes                                               2                             4                          
  **After surgery**                                                                                           
   No                                               57                            93                    **0.0040**
   Yes                                              10                             2                          
  **Stage**                                                                                               0.8016
  0                                                  1                             4                          
  I                                                 26                            35                          
  II                                                25                            39                          
  III                                               11                            13                          
  IV                                                 2                             4                          
  NA                                                 2                             0                          
  **Tumour stage**                                                                                        0.0921
  T0                                                 2                             5                          
  T1                                                34                            49                          
  T2                                                22                            39                          
  T3                                                 5                             0                          
  T4                                                 2                             0                          
  TX                                                 2                             2                          

Abbreviations: DCIS=ductal carcinoma *in situ*; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; NA=not applicable. Bold represents statistical significance.

###### Dysregulated miRs in TNBC when compared with normal and non-TNBC

  **Downregulated miRs**    **TNBC/normal**   **TNBC/non-TNBC**
  ------------------------ ----------------- -------------------
  miR-21                         0.14               0.02
  miR-16                         0.16               0.03
  miR-143                        0.06               0.03
  miR-185                        0.16               0.03
  miR-199a-3p                    0.12               0.05
  miR-199a-5p                     0.1               0.05
  miR-221                        0.12               0.05
  **Upregulated miRs**                       
  miR-92a-3p                      6.1               2.03
  miR-23b-3p                     1.15               18.53
  miR-342-3p                     6.68               23.81

Abbreviations: miR=miRNA; TNBC=triple-negative breast cancer.
